Fluconazole | Mikomaks capsules 150 mg 3 pcs.

Packing

3 pcs

Indications of

cryptococcosis, including cryptococcal meningitis and other localizations of this infection (including in the lungs, on the skin), as in patients with a normal immune response, and with various forms of immunosuppression (including in patients with AIDS, during organ transplantation), the drug can be used to prevent cryptococcal infection in AIDS patients

generalized candidiasis, including candidaemia, disseminated candidiasis and other forms of invasive candida infections (infections of the peritoneum, endocardium , eyes, respiratory and urinary tract) candiduria. Treatment can be carried out in patients with malignant neoplasms, patients in intensive care units, patients undergoing a course of cytostatic or immunosuppressive therapy, as well as in the presence of other factors predisposing to the development of candidiasis

candidiasis of the mucous membranes, including the oral cavity and pharynx (including atrophic candidiasis of the oral cavity associated with wearing dentures), the esophagus, non-invasive bronchopulmonary candidiasis prevention of recurrence of oropharyngeal candidiasis in AIDS patients

genital candidiasis: vaginal candidiasis (acute and chronic recurrent), prophylactic use to reduce the frequency of relapse of vaginal candidiasis (3 or more episodes per year) candidal balanitis with malignant fungal infections neoplasms that are predisposed to such infections as a result of chemotherapy with cytostatics or radiation therapy of

mycosis of the skin, including th tinea pedis, body, groin, pityriasis versicolor, onychomycosis skin candidiasis

deep endemic mycoses, including coccidioidomycosis, paracoccidioidomycosis, sporotrichosis and histoplasmosis in patients with normal immune systems.

Contraindications

hypersensitivity to the drug or structurally similar azole compounds

simultaneous administration of terfenadine or astemizole and other drugs that extend the QT

interval for children (up to 3 years).

Precautions: hepatic and / or renal failure, concomitant use of potentially hepatotoxic drugs, alcoholism.

Special instructions

In rare cases, the use of Mikomax was accompanied by toxic effects on the liver, including and fatal, mainly in patients with serious concomitant diseases. During treatment, it is necessary to control liver function. If there are signs of liver damage that may be associated with taking fluconazole, the drug should be discontinued.

Composition

1 capsule contains:

Active ingredient: fluconazole 150 mg

Excipients: lactose monohydrate starch pregelatinized silicon dioxide colloidal magnesium sodium stearate lauryl sulfate.

full-time action

From the digestive system: taste changes, vomiting, nausea, diarrhea, flatulence, abdominal pain, rarely - impaired liver function (jaundice, hepatitis, hepatonecrosis, hyperbilirubinemia, increased activity of ALT, AST, alkaline phosphatase).

From the nervous system: headache, dizziness, rarely - cramps.

From the hemopoietic organs: rarely - leukopenia, thrombocytopenia, neutropenia, agranulocytosis.

Allergic reactions: skin rash, rarely - malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), anaphylactoid reactions.

Other: rarely - impaired renal function, alopecia, hypercholesterolemia, hypertriglyceridemia, hypokalemia.

Drug interaction

When using fluconazole with warfarin, the increase in PV (on average by 12%). In this regard, it is recommended to carefully monitor the PV indicators in patients receiving the drug in combination with coumarin anticoagulants.

Fluconazole increases the plasma half-life of oral hypoglycemic sulfonylurea derivatives (chlorpropamide, glibenclamide, glipizide, tolbutamide) in healthy people. The combined use of fluconazole and oral hypoglycemic agents in patients with diabetes is allowed, but the doctor should keep in mind the possibility of developing hypoglycemia.

The simultaneous use of fluconazole and phenytoin can lead to an increase in the concentration of phenytoin in the plasma to a clinically significant degree. Therefore, if it is necessary to use these drugs together, it is necessary to monitor phenytoin concentrations with dose adjustment in order to maintain the drug level within the therapeutic interval.

Combination with rifampicin reduces AUC by 25% and shortens plasma T1 / 2 of fluconazole by 20%. Therefore sick receiving rifampicin at the same time, it is advisable to increase the dose of fluconazole.

It is recommended to monitor the concentration of cyclosporine in the blood in patients receiving fluconazole, as the use of fluconazole and cyclosporine in patients with a transplanted kidney (when taking fluconazole at a dose of 200 mg / day) leads to a slow increase in the concentration of cyclosporine in plasma.

Patients who receive high doses of theophylline or who are likely to develop theophylline intoxication should be monitored for the early detection of symptoms of theophylline overdose, as taking fluconazole leads to a decrease in the average clearance rate of theophylline from plasma.

With the simultaneous use of fluconazole and terfenadine, cisapride, cases of adverse reactions from the heart have been described, including paroxysms of ventricular tachycardia (torsades de pointes).

The simultaneous use of fluconazole and hydrochlorothiazide can lead to an increase in the concentration of fluconazole in plasma by 40%.

There are reports of the interaction of fluconazole and rifabutin, accompanied by an increase in serum levels of the latter. With the simultaneous use of fluconazole and rifabutin, cases of uveitis have been described. It is necessary to carefully observe patients simultaneously receiving rifabutin and fluconazole.

In patients receiving a combination of fluconazole and zidovudine, there is an increase in the concentration of zidovudine, which is caused by a decrease in the conversion of the latter to its main metabolite, so an increase in side effects of zidovudine should be expected.

Overdose

Symptoms: hallucinations, paranoid behavior.

Treatment: symptomatic, gastric lavage, forced diuresis. Hemodialysis reduces plasma concentrations by about 50% for 3 hours.

Storage Conditions

Keep out of the reach and sight of children, dry, protected from light, at 10 to 25 РC.

Shelf life

3 years.

Deystvuyushtee substance

Fluconazole

Terms and conditions

without prescription

dosage form

capsules

Possible product names

MIKOMAX 0.15 N3 CAPS

Mikomax 150mg Caps. X3 (R)

Mikomaks 150mg No. 3 caps

MIKOMAKS 150MG. No. 3 CAPS.

Mikomax caps 150mg N3